公开(公告)号：US20100144708A1

公开(公告)日：2010-06-10

申请号：US12376889

申请日：2007-08-10

申请人： Gyoon Hee Han ,  Eun Hyun Choi ,  Jee Sun Yang ,  Sung Hee Hong ,  Myung Sook Kim ,  Mi Sun Won ,  Kyung Sook Chung ,  Dong Myung Kim ,  Hyang Sook Yoo ,  Hwan Mook Kim ,  Song Kyu Park ,  Ki Ho Lee ,  Chang Woo Lee ,  Youn Woong Choi ,  Yong Mi Jeong ,  Byung Gu Min

发明人： Gyoon Hee Han ,  Eun Hyun Choi ,  Jee Sun Yang ,  Sung Hee Hong ,  Myung Sook Kim ,  Mi Sun Won ,  Kyung Sook Chung ,  Dong Myung Kim ,  Hyang Sook Yoo ,  Hwan Mook Kim ,  Song Kyu Park ,  Ki Ho Lee ,  Chang Woo Lee ,  Youn Woong Choi ,  Yong Mi Jeong ,  Byung Gu Min

IPC分类号： A61K31/551 ,  C07D243/08 ,  C07D211/96 ,  A61K31/4965 ,  A61P35/04

CPC分类号： C07D295/185 ,  C07D243/08 ,  C07D295/26

摘要： The present invention relates to new heterocyclic compounds containing nitrogen atoms or pharmaceutically acceptable salts thereof, a process for the preparation thereof, and a pharmaceutical composition comprising the same for treatment of cancer. The compounds according to the present invention induce DNA damage due to reactive oxygen species to activate c-abl and p53, induce RhoB to generate apoptosis, and induce cell death by down-regulating Bcl2 involved in cell survival, which is generated by dysregulated signals via the mitochondria pathway, thereby inhibiting tumor cell growth and inducing apoptosis. Accordingly, the composition according to the present invention can be used to treat cancer.

摘要翻译： 本发明涉及含有氮原子的新的杂环化合物或其药学上可接受的盐，其制备方法和包含其的用于治疗癌症的药物组合物。 根据本发明的化合物诱导由于活性氧物质引起的DNA损伤以激活c-abl和p53，诱导RhoB产生凋亡，并通过下调参与细胞存活的Bcl2诱导细胞死亡，其由失调信号通过 线粒体途径，从而抑制肿瘤细胞生长并诱导细胞凋亡。 因此，本发明的组合物可用于治疗癌症。

公开(公告)号：US20090069389A1

公开(公告)日：2009-03-12

申请号：US12180720

申请日：2008-07-28

申请人： Youn Woong CHOI ,  Byung Hwan RYOO ,  Yong Mi JEONG ,  Jae Sang JANG

发明人： Youn Woong CHOI ,  Byung Hwan RYOO ,  Yong Mi JEONG ,  Jae Sang JANG

IPC分类号： A61K31/455 ,  A61P9/10

CPC分类号： A61K31/455 ,  A61K9/2027 ,  A61K9/2054

摘要： The present invention relates to a controlled-release niacin formulation. In particular, the present invention relates to a controlled-release niacin formulation, comprising niacin; hydroxypropyl methylcellulose; and a carboxyvinyl polymer, in which the carboxyvinyl polymer and hydroxypropyl methylcellulose are contained in a predetermined weight ratio, and to a preparation method thereof.The controlled-release niacin formulation according to the present invention maintains its matrix shape until completion of release, and maintains its release pattern without fluctuation for a desired time period, unlike a commercial formulation. In particular, since niacin formulations are used for long-term treatment of hyperlipidemia, the controlled-release niacin formulation of the present invention, capable of maintaining effective blood concentration and high stability for a long period of time, is very useful.

摘要翻译： 本发明涉及一种控释烟酸制剂。 特别地，本发明涉及一种控释烟酸制剂，其包含烟酸; 羟丙基甲基纤维素; 羧基乙烯基聚合物及其制备方法，其中羧乙烯基聚合物和羟丙基甲基纤维素以预定的重量比包含。 根据本发明的控释烟酸制剂保持其基质形状直到释放完成，并且与商业制剂不同，保持其释放模式不变，持续所需时间。 特别是，由于将烟酸制剂用于高脂血症的长期治疗，所以本发明的能够长时间保持有效血药浓度和高稳定性的控释烟酸制剂是非常有用的。